The effects of exogenous CCK-8 on the acquisition and expression of morphine-induced CPP

被引:18
作者
Wen, Di [1 ]
Cong, Bin [1 ]
Ma, Chunling [1 ]
Yang, Shengchang [1 ]
Yu, Hailei [1 ]
Ni, Zhiyu [1 ]
Li, Shujin [1 ]
机构
[1] Hebei Med Univ, Hebei Key Lab Forens Med, Dept Forens Med, Shijiazhuang 050017, Peoples R China
关键词
Cholecystokinin octapeptide; Morphine; Conditioned place preference; Acquisition; Expression; Reward; CHOLECYSTOKININ-LIKE MATERIAL; PLACE PREFERENCE; B RECEPTORS; DEPENDENCE; ANTAGONIST; TOLERANCE; ANALGESIA;
D O I
10.1016/j.neulet.2011.12.063
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Cholecystokinin octapeptide (CCK-8) is the most potent endogenous anti-opioid peptide and regulates a variety of physiological processes. In our previous study, we found that exogenous CCK-8 attenuated naloxone-induced withdrawal symptoms, but the possible regulative effects of CCK-8 on the rewarding effects of morphine were not examined. In the present study, we aimed to determine the exact effects of exogenous CCK-8 at various doses on the rewarding action of morphine by utilizing the unbiased conditioned place preference (CPP) paradigm. We therefore examined the effects of CCK-8 on the acquisition, expression and extinction of morphine-induced CPP and on locomotor activity. The results showed that CCK-8 (0.01-1 mu g, i.c.v.), administered alone, induced neither CPP nor place aversion, but blocked the acquisition of CPP when administered with 10 mg/kg morphine. The highest dose of CCK-8 (1 mu g) administered before CPP testing increased CPP and, along with lower doses (0.1 mu g), reduced its extinction. In addition, the highest dose (1 mu g) of CCK-8 suppressed locomotor activity. Our study provides the first behavioral evidence for the inhibitory effects of exogenous CCK-8 on rewarding activity and reveals significant effects of exogenous CCK-8 on various stages of place preference and the development of opioid dependence. (C) 2012 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:24 / 28
页数:5
相关论文
共 31 条
[1]   Effect of CCK1 and CCK2 receptor blockade on amphetamine-stimulated exploratory behavior and sensitization to amphetamine [J].
Alttoa, A ;
Harro, J .
EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2004, 14 (04) :324-331
[2]   δ-Opioid receptor-mediated increase in cortical extracellular levels of cholecystokinin-like material by subchronic morphine in rats [J].
Becker, C ;
Pohl, M ;
Thiébot, MH ;
Collin, E ;
Hamon, M ;
Cesselin, F ;
Benoliel, JJ .
NEUROPHARMACOLOGY, 2000, 39 (02) :161-171
[3]   OPIOID CONTROL OF THE INVITRO RELEASE OF CHOLECYSTOKININ-LIKE MATERIAL FROM THE RAT SUBSTANTIA-NIGRA [J].
BENOLIEL, JJ ;
MAUBORGNE, A ;
BOURGOIN, S ;
LEGRAND, JC ;
HAMON, M ;
CESSELIN, F .
JOURNAL OF NEUROCHEMISTRY, 1992, 58 (03) :916-922
[4]   BIOLOGICAL ACTIONS OF CHOLECYSTOKININ [J].
CRAWLEY, JN ;
CORWIN, RL .
PEPTIDES, 1994, 15 (04) :731-755
[5]   Behavioral profile of CCK2 receptor-deficient mice [J].
Daugé, V ;
Sebret, A ;
Beslot, F ;
Matsui, T ;
Roques, BP .
NEUROPSYCHOPHARMACOLOGY, 2001, 25 (05) :690-698
[6]   Cholecystokinin receptors mediate tolerance to the analgesic effect of TENS in arthritic rats [J].
DeSantana, Josimari M. ;
da Silva, Luis Felipe S. ;
Sluka, Kathleen A. .
PAIN, 2010, 148 (01) :84-93
[7]   THE SELECTIVE CCK-B RECEPTOR ANTAGONIST L-365,260 ENHANCES MORPHINE ANALGESIA AND PREVENTS MORPHINE-TOLERANCE IN THE RAT [J].
DOURISH, CT ;
ONEILL, MF ;
COUGHLAN, J ;
KITCHENER, SJ ;
HAWLEY, D ;
IVERSEN, SD .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1990, 176 (01) :35-44
[8]   EVIDENCE FOR THE NEUROPEPTIDE CHOLECYSTOKININ AS AN ANTAGONIST OF OPIATE ANALGESIA [J].
FARIS, PL ;
KOMISARUK, BR ;
WATKINS, LR ;
MAYER, DJ .
SCIENCE, 1983, 219 (4582) :310-312
[9]  
Hadjiivanova Christina, 2003, Acta Physiol Pharmacol Bulg, V27, P83
[10]   Cholecystokinin and endogenous opioid peptides: Interactive influence on pain, cognition, and emotion [J].
Hebb, ALO ;
Poulin, JF ;
Roach, SP ;
Zacharko, RM ;
Drolet, G .
PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY, 2005, 29 (08) :1225-1238